A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma
Clinical trial NCT05376800 · COMPLETED
Trial details
- NCT number
- NCT05376800
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-30
- Primary completion
- 2025-07-31
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.